This study aims to characterize current treatment patterns and clinical outcomes among newly diagnosed GEP-NET patients in the United States using open-source Longitudinal Prescription Claims (LRx) and Patient Centric Medical Claims (Dx) databases supplemented with mortality data.
Study Type
OBSERVATIONAL
Enrollment
4,023
Number of Lines of Therapy (LOTs)
Time frame: Up to approximately 8 years
Number and Percentage of Patients by Treatment Regimen per LOT
Time frame: Up to approximately 8 years
Number and Percentage of Patients by Type of Therapy in Each LOT
Time frame: Up to approximately 8 years
Number and Percentage of Patients who Discontinue all Medications Within the 1L Treatment Regimen
Time frame: Up to approximately 8 years
Number of Cycles of Medications Within the Treatment Regimen Before Discontinuation
Time frame: Up to approximately 8 years
Time to 1L Treatment Discontinuation
Time frame: Up to approximately 8 years
Duration Between GEP-NET Diagnosis and 1L Treatment
Time frame: Baseline
Number and Percentage of Patients who Switch Treatment From 1L to Fifth-line (5L) Treatment
Time frame: Up to approximately 8 years
Number and Percentage of Patients With Addition of Other Therapies While on Initial 1L Therapy
Time frame: Up to approximately 8 years
Time to Next Treatment (TTNT)
Time frame: Up to approximately 8 years
Overall Survival (OS)
Novartis Pharmaceuticals
CONTACT
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
OS calculated as the number of weeks from the start of treatment until death.
Time frame: Up to approximately 8 years
Number and Percentage of Patients by Demographics
Demographics include: * Age group (18-34, 35-44, 45-54, 55-64, 65+ years) * Sex * Geographic region * Payer type * Race/ethnicity * Education level * Occupation * Marital status
Time frame: Baseline
Age
Time frame: Baseline
Duration of Follow-up
Time frame: Up to approximately 8 years
Number and Percentage of Patients by Clinical Characteristics
Clinical characteristics include: * National Cancer Institute (NCI) comorbidity index category (0, 1, 2, 3+) * Comorbidities * Treating provider specialty * Metastatic sites (bone, visceral, lymph node, liver) * Number of distinct metastatic sites (0, 1, 2, 3, 4+)
Time frame: Baseline
NCI Comorbidity Index Score
The NCI comorbidity index is a tool used to measure the risk of non-cancer deaths for cancer patients based on the presence and severity of other health conditions. It includes 14 conditions identified using administrative data diagnosis and procedure codes. The index excludes solid tumors, leukemias, and lymphomas as comorbid conditions. Each condition is assigned a score (from 1 to 6) based on how serious it is and patient scores are summed to give a final overall score. A high score indicates a higher burden of comorbid conditions and possible higher risk of death.
Time frame: Baseline